Dr. John Cush RheumNow
2 years 10 months ago
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/XdHmARnxpu https://t.co/N7Bm5GIgjd
Dr. John Cush RheumNow
2 years 10 months ago
RHEUM Survey: In Newly Dx #PMR patients, How many do you do imaging for GCA vascular involvement?
Dr. John Cush RheumNow
2 years 10 months ago
Looks like #PMR - But is it?
Patients referred to rheumatologists for suspected PMR - but is it? And what's the role of imaging to help make the diagnosis?
https://t.co/oinfFXE978 https://t.co/4aAHrYbjZD
Dr. John Cush RheumNow
2 years 10 months ago
Could Methotrexate Work in Hand Osteoarthritis?
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
https://t.co/GhVB7WzJLQ https://t.co/Lt0pvm3RCW
Dr. John Cush RheumNow
2 years 10 months ago
12.3 million Americans over 50 have osteoporosis; 47 million have osteopenia. W/ OP Fx the risk of repeat Fx is highest in 1st 6 mos, yet 8% of Medicare pts w/ Fx have a diagnostic bone density scan (less in African Americans 5%) https://t.co/2mogEEk3tq https://t.co/9tjwXg0WzZ https://t.co/ruLnjm4kXr
Dr. John Cush RheumNow
2 years 10 months ago
Tuesday Nite Rheumatology webinar on the use of steroid-sparing drugs in patients with #PMR.
Featuring Panelists: Drs. David Liew, Robert Spiera, Sarah Mackie, Anisha Dua
Moderator: Dr. Sebastian Sattui
https://t.co/HDXCG1bq2m https://t.co/95vfTnXtNP
Dr. John Cush RheumNow
2 years 10 months ago
Tocilizumab Use in #GCA. In 10 yrs, 114 GCA pts started on TCZ after mean 4.5 mos & Rx for 2.3 yrs. GCA Relapse rates:
- before TCZ 0.84/PY
- on TCZ 0.28/PY (P<0.001)
- post TCZ D/C 0.64/PY
52 pts D/C TCZ after 16.8 mos & 27 (52%) relapsed after 8.4 mo https://t.co/D3INiMdC4U https://t.co/aD2rijR6xd
Dr. John Cush RheumNow
2 years 10 months ago
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/9TEUOODO1P https://t.co/5IhVmOpTCB
What causes polymyalgia rheumatica? It could be said that PMR occurs when trajectories of aging take a wrong turn, but it’s still not clear exactly what it is that causes this to happen. The ideas that follow will doubtless seem, to immunologists, vague and oversimplified; but even a partial picture might still offer a possible framework for clinicians and patients for thinking about treatment and care.
Dr. John Cush RheumNow
2 years 10 months ago
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF
UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
Dr. John Cush RheumNow
2 years 10 months ago
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt
